Bempedoic Acid
Bempedoic acid
Bempedoic acid receives broader indications from FDA
Esperion Therapeutics announced the FDA approved broad label expansion for bempedoic acid and bempedoic acid/ezetimibe for CV risk reduction and LDL lowering in both primary and secondary prevention populations.
Top in cardiology: Caregiver support linked to better CV health; rate in CV deaths slows
A study recently showed that adults who experienced abuse or neglect from caretakers were less likely to have ideal cardiovascular health.
New CLEAR Outcomes data: Bempedoic acid cuts risk for recurrent CV events
A prespecified analysis of the CLEAR Outcomes trial shows that the benefits of bempedoic acid extend to patients with recurrent CV events, including a total reduction in MI risk of 31% vs. placebo.
Top cardiology news in 2023: A year of firsts for CVD treatments, procedures, devices
Healio | Cardiology Today compiled a list of some of the most important news in cardiology from 2023.
Top news in December: Dental health and CVD risk; expanded bempedoic acid indication; more
Healio and Cardiology Today have compiled a list of the most-read news in cardiology in December 2023.
Targeting obesity may be ‘highly effective strategy’ for treating HFpEF, ASCVD
Findings from two cardiovascular outcome trials revealed that targeting obesity could become a major focus for treating cardiovascular disease and heart failure with preserved ejection fraction in the future, according to a speaker.
FDA approves expanded indications for bempedoic acid and combination tablet
Esperion announced the FDA granted an updated indication for bempedoic acid and bempedoic acid plus ezetimibe for the treatment of primary hyperlipidemia in eligible patients with genetic hyperlipidemia or atherosclerotic CVD.
Part of the Healio Network
Bempedoic Acid Topic Review
Bempedoic acid (Nexletol, Esperion Therapeutics) is a nonstatin low-density lipoprotein cholesterol (LDL-C)-lowering drug.
Inflammation predicts events more than cholesterol in high-risk statin-intolerant patients
PHILADELPHIA — In the CLEAR Outcomes cohort of patients with statin intolerance, inflammation predicted risk for CV events and death more strongly than cholesterol, researchers reported at the American Heart Association Scientific Sessions.